-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
First Comprehensive Genomic Profiling Assay Approved for Use with Brigatinib, ALK-positive NSCLC
July 1, 2021—The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx for use as a companion diagnostic for brigatinib, which the FDA had previously approved for treatment of adult patients with ALK-positive NSCLC. FoundationOne CDx is a tissue-based comprehensive genomic profiling assay and is the first of this kind to receive FDA approval.…
-
High-Dose Once-Daily Thoracic Radiotherapy Did Not Improve OS in Limited Stage SCLC
High-dose 70 Gy once-daily thoracic radiotherapy did not significantly improve OS compared with the current standard of 45 Gy twice-daily radiotherapy in patients with limited-stage SCLC, according to results of the CALGB 30610 (Alliance)/RTOG 0538 trial. “Outcomes in the 70 Gy cohort do provide the best evidence available in support of high-dose once-daily thoracic radiotherapy…
-
Single Institution’s Experience: SABR Shows Outstanding OS vs. VATS in Patients with Early-Stage NSCLC
Treatment of operable, stage-I NSCLC with stereotactic ablative radiotherapy (SABR) was noninferior to video-assisted thoracic surgery (VATS) with mediastinal lymph node dissection (L-MLND). Joseph Y. Chang, MD, of The University of Texas MD Anderson Cancer Center, presented the results of a single-arm trial comparing SABR with a published, longitudinally followed institutional cohort of patients treated…
-
Awareness-raising Bike Ride in The Netherlands Connected Hospitals, Patients
Patients and supporters cycled nearly 1,150 kilometers through The Netherlands on May 21, 2021 in a “White Ribbon Tour” to raise awareness for lung cancer. The grassroots event was organized by Niels Harthoorn, age 22, an industrial engineering and management student at the University of Twente, and a patient with lung cancer. For the ride,…
-
Understanding and Targeting SCLC
Lung cancer is the leading cause of cancer mortality worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018—more than colon, breast, and prostate cancers combined.1 SCLC is a high-grade neuroendocrine carcinoma, typically metastatic at diagnosis; it has an exceptionally poor prognosis, with a dismal median OS of approximately 1 year.2…
-
KRAS: Old Target, New Hope
As more data emerge and more investigational drugs are studied, the “undruggable” target is coming into focus.
-
Prophylactic Radiotherapy: A Case for Patients at High Risk of Brain Metastases
Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel targeted therapies that have shifted the outlook for patients with oncogene-addicted lung adenocarcinomas. However, a recently published randomized clinical trial is generating debate among clinicians…
-
IMpower010: Adjuvant Atezolizumab Improved DFS in PD-L1 Expressing Stage II-IIIA NSCLC
Adjuvant atezolizumab significantly improved disease-free survival (DFS) compared with best supportive care after chemotherapy in patients with resected stage II-IIIA NSCLC, according to the results of the IMpower010 study presented at 2021 ASCO Annual Meeting (Abstract 8500). 1 “IMpower010 is the first phase III study of cancer immunotherapy to demonstrate disease-free survival improvement in the adjuvant…
-
Selpercatinib Approved in Canada for Metastatic NSCLC with RET Fusions
June 15, 2021—Canada’s medical regulatory agency approved the use of selpercatinib monotherapy for treatment of patients with metastatic RET fusion–positive NSCLC. Health Canada based its conditional approval on the LIBRETTO-001 phase I/11 trial, with two phase III trials pending to confirm clinical benefit. LIBRETTO-001, a multicenter, open-label, multicohort trial, enrolled 144 patients with advanced RET…
-
Molecular Resistance Mechanisms to EGFR, ALK, and ROS1 TKIs
The identification of activating EGFR mutations and ALK and ROS1 rearrangements has ushered in an era of precision medicine for advanced NSCLC characterized by swift advances and adaptive drug development. However, most patients with tumors harboring these genomic alterations derive durable, yet not indefinite, benefit from targeted therapies. Molecular and histologic evaluation at baseline and…